Shattuck Labs stock (US8124231002): FDA orphan drug designation and sector backdrop

Shattuck Labs shares trade on Nasdaq in the United States as investors digest the recent U.S. FDA orphan drug designation for SL-172154 in acute myeloid leukemia and broader biotech sector moves. The stock’s development-stage profile keeps focus on clinical milestones and financing capacity.

Shattuck Labs, listed on Nasdaq under the ticker STTK, remains in focus for U.S. investors after the company recently reported that the U.S. Food and Drug Administration granted orphan drug designation to its investigational candidate SL-172154 for the treatment of acute myeloid leukemia, underscoring the development-stage biotech's oncology pipeline in its home market the United States, according to a company press release dated 04/30/2024 on the investor relations site and a corresponding update on 05/01/2024 on Nasdaq.

The stock traded at USD 3.35 on 05/28/2026 on Nasdaq, reflecting modest intraday movement as investors weighed the implications of the designation alongside overall sentiment toward smaller-cap U.S. biotechnology names, according to Nasdaq price data as of 05/28/2026 and complementary coverage from Reuters as of 05/28/2026.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Shattuck Labs
• Sector/industry: Biotechnology - oncology-focused clinical-stage therapeutics
• Headquarters/country: Austin, United States
• Core markets: North American and global oncology drug development and partnering
• Key revenue drivers: Pipeline collaboration income and potential future commercialization of immuno-oncology candidates
• Home exchange/listing venue: Nasdaq (STTK)
• Trading currency: USD

Shattuck Labs: core business model

Shattuck Labs concentrates on discovering and advancing immuno-oncology drug candidates, with value creation centered on progressing its clinical pipeline and securing partnerships that could translate experimental programs into commercial-stage therapies.

Industry trends and competitive position

The orphan drug designation for SL-172154 highlights Shattuck Labs' positioning within the competitive immuno-oncology segment of the global biotechnology industry, where regulators such as the U.S. FDA have continued to use incentives like orphan status, fast-track and breakthrough designations to stimulate development for serious and rare diseases, a trend documented in FDA oncology approvals and policy updates through 2024 and 2025.

Within this framework, Shattuck Labs competes and collaborates with a broad field of biotechnology and large pharmaceutical companies investing heavily in antibody-based and immune-modulating treatments for hematologic malignancies, as evidenced by sector-wide R&D and deal activity reported by S&P Global Market Intelligence and industry analyses from Evaluate Vantage in 2025 that point to sustained capital flows into oncology and rare-disease assets, even as investors remain selective on smaller issuers with limited revenue and a reliance on clinical milestones and capital markets access.

Conclusion

The recent FDA orphan drug designation for SL-172154 in acute myeloid leukemia keeps attention on Shattuck Labs' U.S.-based immuno-oncology pipeline and its efforts to progress early-stage assets through clinical development. Against a backdrop of active but selective capital allocation to oncology and rare-disease projects across the biotechnology sector, the company’s future share performance is likely to depend on trial readouts, regulatory interactions and its ability to secure funding or partnerships on competitive terms.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.